Acorda Therapeutics Investor Relations Material
Latest events
Q3 2023
Acorda Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Acorda Therapeutics Inc
Access all reports
Acorda Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for neurological disorders in the United States. The company's lead product is Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS). It also develops ARCUS product for the treatment of acute migraines; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. Acorda Therapeutics' other collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics was incorporated in 1995 and is headquartered in Ardsley, New York.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
ACOR
Country
🇺🇸 United States